Health
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies – PRNewswire
/PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the…
NEW BRUNSWICK, N.J., July 30, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and provi…
-
General24 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
Noosa News9 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News23 hours agoPolice charge second man over alleged assault in Gold Coast car seller on Facebook’s Marketplace
-
General23 hours agoRecord Qantas fine reveals Australia’s perverse moral compass